"novel mechanisms targeted by drug trials in pulmonary arterial hypertension"
Chest. 2021 Oct 13:S0012-3692(21)04093-9. doi: 10.1016/j.chest.2021.10.010. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a rare disease associated with abnormally elevated pulmonary pressures and right heart failure resulting in high morbidity and mortality. While PAH prognosis has improved with the introduction of pulmonary vasodilators, disease progression remains a major problem. Given that available therapies are inadequate for preventing small vessel loss and obstruction, there is an active interest in identifying drugs capable of targeting angiogenesis and mechanisms involved in regulation o...
Source: Chest - October 16, 2021 Category: Respiratory Medicine Authors: David F Condon Stuti Agarwal Ananya Chakraborty Natasha Auer Rocio Vazquez Hiral Patel Roham T Zamanian Vinicio A de Jesus Perez David F Condon Source Type: research
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)
CONCLUSION: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.PMID:34625284 | DOI:10.1016/j.ygyno.2021.09.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2021 Category: Cancer & Oncology Authors: R J Edmondson R L O'Connell S Banerjee L Mileshkin P Sykes P Beale A Fisher A Bonaventura D Millan S Nottley C Benson A Hamilton K Sjoquist L Alexander C Kelly K Carty L Divers N Bradshaw M Friedlander PARAGON investigators Source Type: research
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)
CONCLUSION: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.PMID:34625284 | DOI:10.1016/j.ygyno.2021.09.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2021 Category: Cancer & Oncology Authors: R J Edmondson R L O'Connell S Banerjee L Mileshkin P Sykes P Beale A Fisher A Bonaventura D Millan S Nottley C Benson A Hamilton K Sjoquist L Alexander C Kelly K Carty L Divers N Bradshaw M Friedlander PARAGON investigators Source Type: research
Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years
ConclusionSimilar disease free survival and overall survival were observed among the three studied groups. Switching tamoxifen to aromatase inhibitors provides better tolerability in terms of endometrial thickness when compared to 5 years of tamoxifen monotherapy. Patients who administer aromatase inhibitor included in the switching strategy experience less osteoporosis and less generalized bone pain compared to upfront aromatase inhibitor to 5 years. There was a significant improvement of disease free survival (DFS) in human epidermal growth factor receptor 2 (HER 2) negative patients receiving any adjuvant hormonal treat...
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation
This study evaluated the risk of major bleeding associated with concomitant use of direct oral anticoagulant (DOAC) and anticancer drugs (ACDs), which share metabolic pathways, in patients with atrial fibrillation (AF) and cancer. We performed a retrospective cohort study using Taiwan ’s National Health Insurance database and included patients with AF and cancer who received DOAC prescriptions from 1 to 2012 to 31 December 2017. The incidence of major bleeding in person-quarters with concomitant use of DOAC and any of 15 ACDs with inhibitory or competitive effects of CYP3A4 or P-gp activity (docetaxel, vinorelbine, metho...
Source: Journal of Thrombosis and Thrombolysis - September 23, 2021 Category: Hematology Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clin Med Res)
Source: Clin Med Res - September 15, 2021 Category: Research Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clin Med Res)
Source: Clin Med Res - September 15, 2021 Category: Research Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
CONCLUSIONS: High sTK1 at BL and subsequent time-points is associated with worse prognosis in MBC patients starting 1st line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single agent or combination ET.PMID:34521624 | DOI:10.1158/1078-0432.CCR-21-1562 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research
